GLP-1 Weight-Loss Drugs Trigger Structural Shift in Consumer Spending

The proliferation of GLP-1 weight-loss medications is evolving from a healthcare trend into a significant macroeconomic disruptor, altering how millions of Americans allocate their disposable income. As these drugs suppress appetite and cravings, the emerging 'Ozempic economy' is creating a stark divide between sectors that rely on caloric consumption and those that benefit from increased physical activity. The restaurant sector is feeling the direct impact of this shift. Chipotle Mexican Grill (CMG) has reported flat or negative same-store sales growth over the last four quarters, contributing to a 50% decline in its stock price from previous highs. In response, chains are attempting to pivot toward high-protein, lower-calorie menu options to retain health-conscious consumers, though the long-term impact on total caloric intake remains a concern for the industry. Conversely, the fitness industry is experiencing a significant tailwind. Planet Fitness (PLNT) reported a 171% cumulative revenue increase over the last five years, with 1.1 million new members joining in 2025. The company is guiding for 180 to 190 new club locations in 2026, with projected same-club sales growth of 4% to 5%. Currently, the company maintains a price-to-earnings ratio of 28.5 with $220 million in net earnings over the last 12 months. With new oral medications and more potent drugs such as retatrutide in the pipeline from Eli Lilly, the shift in consumer behavior may be permanent. Investors are now weighing the long-term viability of traditional calorie-heavy business models against the growth potential of the wellness economy.